bdb001
Virus-associated Tumors
Institut BergoniéPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Virus-associated Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atezolizumab Institut Bergonié | Phase 2 | CCC |
Pembrolizumab Medicenna Therapeutics, Inc. | Phase 1/2 | CCC |
Mdna11 Medicenna Therapeutics, Inc. | Phase 1/2 | CCC |
Abi-007 Celgene | Phase 1 | CC |
Azacitidine Celgene | Phase 1 | CC |
View all 9 →
Same molecule, other indications
bdb001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →